talkbio – Page 21

FDA Institutes Stricter, Targeted COVID Vaccine Policy, Moving Away from ‘One-Size-Fits-All’ Approach

2 months ago talkbio0Tagged Clinical Trials, COVID19 (disease), Elderly (population group), Eligibility Determination, high-risk groups, Policy, public health medicine (field), United States Food and Drug Administration, Vaccines

FDA; COVID-19; vaccine policy; vaccine eligibility; clinical trials; high-risk groups; elderly; policy change; public health

Genentech Bets Again on Orionis With Potential $2B+ in Crowded Molecular Glue Space

2 months ago talkbio0Tagged Allo-Glue platform, Drug Discovery, genentech, Malignant Neoplasms, molecular glue, Neoplasms, Orionis Biosciences, Partnership, protein degraders

Genentech; Orionis Biosciences; molecular glue; oncology; drug discovery; cancer; partnership; biotech; protein degraders; Allo-Glue platform

Korro Bio Lays Off 20% of Workforce to Extend Runway for Genetic Medicine Trials and Novo Nordisk Partnership

2 months ago talkbio0Tagged alpha 1-Antitrypsin Deficiency, Clinical Trials, Genetic Medicine, Korro Bio, KRRO-110, layoffs, Nordisk, restructuring, RNA Editing

Korro Bio; layoffs; biotech; genetic medicine; RNA editing; KRRO-110; Novo Nordisk; clinical trial funding; restructuring; AATD

Tourmaline Bio’s Heart Drug Pacibekitug Shows Promise Against Cardiovascular Inflammation, Targets Competition with Novo, CSL

2 months ago talkbio0Tagged Cardiovascular system, heart drug, Inflammation, interleukin-6, Markers (device), Nordisk, pacibekitug, Phase 2 trial, SMPX gene, tourmaline, United States Food and Drug Administration

Tourmaline Bio; heart drug; pacibekitug; cardiovascular inflammation; inflammation markers; Novo Nordisk; CSL; Phase 2 trial; FDA; IL-6

Pfizer Pays $1.25B Upfront to 3SBio, Joining the PD-1 x VEGF Race with Licensing Deal for SSGJ-707

2 months ago talkbio0Tagged Cancer Therapeutic Procedure, China, Drug Development, Licensing Deal, Neoplasms, PD-1/VEGF bispecific antibody, Pfizer, SSGJ-707, upfront payment

Pfizer; 3SBio; PD-1/VEGF bispecific antibody; SSGJ-707; oncology; upfront payment; licensing deal; cancer therapy; China; drug development

CRISPR Therapeutics Partners with Sirius for siRNA Therapies, Expanding Beyond Gene Editing

2 months ago talkbio0Tagged Anticoagulants, biotech partnerships, Cardiovascular Diseases, Clustered Regularly Interspaced Short Palindromic Repeats, Factor XI, Gene Modification, RNA, Small Interfering, Sirius, SRSD107, thrombotic disease

CRISPR Therapeutics; Sirius Therapeutics; siRNA; gene editing; SRSD107; cardiovascular diseases; thrombotic disease; biotech partnerships; Factor XI; anticoagulant therapies

Schrödinger Lays Off 60 Staffers Amid Economic Uncertainty

2 months ago talkbio0Tagged Economic Conditions, Financial cost, layoffs, restructuring, Schrödinger, Transection (procedure)

Schrödinger; layoffs; biotech; workforce reduction; economic conditions; cost cutting; restructuring

RegenXBio Secures Up to $250 Million by Monetizing Royalties from Zolgensma and Two Gene Therapies

2 months ago talkbio0Tagged gene therapy, HealthCare Royalty, milestone payments, non-dilutive financing, Regenxbio, RGX-111, RGX-121, royalty monetization, Zolgensma

RegenXBio; Zolgensma; gene therapy; royalty monetization; HealthCare Royalty; RGX-121; RGX-111; non-dilutive financing; biotech; milestone payments

Prime Medicine CEO Exits Amidst Layoffs and Restructuring as Sole Clinical Gene Therapy Shelved

2 months ago talkbio0Tagged CEO, Clinical Trials, Exit, gene therapy, layoffs, pipeline pivot, PM359, Prime Editing, Prime Medicine, restructuring

Prime Medicine; CEO exit; gene therapy; layoffs; restructuring; biotech; PM359; prime editing; clinical trial; pipeline pivot

SpyLock Technology: Recent News on Rapid Bispecific Antibody Screening

2 months ago talkbio0Tagged BiLockCatcher, Bio-Rad, bispecific antibody screening, Drug Development, high-throughput screening, Laboratory, Pioneer Antibody Discovery, Protein Engineering, SpyLock technology, SpyTag/SpyCatcher

SpyLock technology; bispecific antibody screening; Bio-Rad Laboratories; Pioneer Antibody Discovery Platform; high-throughput screening; protein engineering; SpyTag/SpyCatcher; BiLockCatcher; drug development